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Abstract 22 
Dipeptides with a C terminal Pro inhibit dipeptidyl peptidase IV (DPP-IV), a key enzyme in 23 
incretin hormone processing. It was hypothesised that tri- and tetrapeptides with a proline at the 24 
C-terminus may also be DPP-IV inhibitors. Therefore, an in silico hydrolysis approach was used 25 
to release short (4 ≤ amino acids) C terminal Pro peptides from the individual caseins which 26 
constitute Pro rich substrates. This was achieved using theoretical digestion of caseins with a 27 
prolyl oligopeptidase activity. Fifteen peptides were subsequently selected for in vitro DPP-IV 28 
inhibitory analysis. Stability of these peptides to gastrointestinal enzymes was also evaluated in 29 
silico and the predicted breakdown peptides were assessed for their DPP-IV inhibitory and 30 
antioxidant potential. New DPP-IV inhibitors were identified, the most potent being Phe-Leu-31 
Gln-Pro (IC50 65.3 ± 3.5 µM). A low in vitro antioxidant (2,2-diphenyl-1-picrylhydrazyl (DPPH) 32 
scavenging) activity was also associated with the peptides studied. The strategy presented 33 
highlights the utility of employing an in silico approach for the prediction of food-derived 34 
peptides with a potential role in glycaemic management for subsequent development of 35 
functional foods. 36 
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1. Introduction 40 
Inhibition of dipeptidyl peptidase IV (DPP-IV) has been exploited as a new therapeutic strategy 41 
in the treatment of Type 2 diabetes (T2D) (Drucker, 2006b; Nauck & El-Ouaghlidi, 2005). DPP-42 
IV can cleave incretins such as glucose dependent insulinotropic polypeptide (GIP) and 43 
glucagon-like peptide-1 (GLP-1). These hormones enhance insulin secretion from pancreatic beta 44 
cells in response to different nutrients (Drucker, 2006a). Different drugs, known as gliptins, are 45 
currently being used as DPP-IV inhibitors for the treatment of T2D (Lacroix & Li-Chan, 2014; 46 
Scheen, 2012). It has also been demonstrated that various food protein-derived peptides, 47 
including animal and plant-derived peptides, have DPP-IV inhibitory properties (Harnedy & 48 
FitzGerald, 2013; Li-Chan, Hunag, Jao, Ho, & Hsu, 2012; Velarde-Salcedo et al., 2013). An in 49 
silico approach demonstrated that various DPP-IV inhibitory peptides may be found within 50 
dietary proteins, including milk proteins (Lacroix & Li-Chan, 2012b). Several studies have 51 
demonstrated that enzymatic hydrolysates of milk proteins were a good source of DPP-IV 52 
inhibitory peptides (Lacroix & Li-Chan, 2013; Lacroix & Li-Chan, 2012a; Nongonierma & 53 
FitzGerald, 2013a; Silveira, Martínez-Maqueda, Recio, & Hernández-Ledesma, 2013; Tulipano, 54 
Sibilia, Caroli, & Cocchi, 2011; Uchida, Ohshiba, & Mogami, 2011; Uenishi, Kabuki, Seto, 55 
Serizawa, & Nakajima, 2012). Recently, interactions between sitagliptin, a DPP-IV inhibitory 56 
drug, and milk-derived peptides were studied, showing an additive effect between sitagliptin and 57 
the milk-derived peptides for DPP-IV inhibition in vitro (Nongonierma & FitzGerald, 2013b). 58 
These studies indicate that food-derived peptides may play an important role in glycaemic 59 
regulation. 60 
Peptide inhibitors of DPP-IV with various amino acid sequences have been reported in the 61 
literature (Lacroix & Li-Chan, 2012b). It has been shown that dipeptides with the sequence Xaa-62 
Pro (with Xaa representing an amino acid) can act as DPP-IV inhibitors. Different dipeptide 63 
sequences with a Pro residue at the C terminus have previously been identified as DPP-IV 64 
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inhibitors (Hatanaka et al., 2012). The casein-derived peptide, Leu-Pro-Gln-Asn-Ile-Pro-Pro 65 
(f70-76), was found to be a DPP-IV inhibitor with an IC50 value of 160 µM (Uenishi et al., 2012). 66 
In addition, various peptide sequences without Pro residues have also been reported as potent 67 
DPP-IV inhibitors (Lacroix & Li-Chan, 2012b; Nongonierma & FitzGerald, 2013a). However, 68 
there appears to be a limited amount of data available in the literature describing the role of short 69 
(4 ≤ amino acids) casein-derived peptides having C terminal Pro residues on DPP-IV inhibition. 70 
The increased oxidative stress associated with T2D may potentiate the development of secondary 71 
complications such as cardiovascular and renal disease (Hayden & Tyagi, 2001). It has been 72 
demonstrated that caseins and casein-derived peptides can scavenge free radicals in vitro (Irshad, 73 
Kanekanian, Peters, & Masud, 2013; Kitts, 2005; Suetsuna, Ukeda, & Ochi, 2000) and increase 74 
cellular catalase activity and glutathione levels in human lymphocyte (Jurkat) cells (Phelan, 75 
Aherne-Bruce, O'Sullivan, FitzGerald, & O'Brien, 2009). Much interest has focused on the role 76 
of dietary antioxidants on health. To date, there appears to be a lack of consensus on the role of 77 
these compounds in vivo (Chang & Chuang, 2010; Power, Jakeman, & FitzGerald, 2013). 78 
However, given the potential of bioactive peptides to display multifunctional activities, we also 79 
investigated the in vitro antioxidant activity of the synthetic peptides. 80 
The aim of this study was to evaluate the ability of selected short (4 ≤ amino acids) C-terminal 81 
Pro containing peptides, predicted in silico to be released from casein, a Pro-rich substrate, on 82 
incubation with prolyl oligopeptidase, to inhibit DPP-IV activity. In addition, the in vitro 83 
antioxidant (DPPH scavenging) activity of these peptides was studied. The DPP-IV inhibitory 84 
peptides evaluated herein were also subjected to in silico analysis to predict their stability to 85 
gastrointestinal enzyme digestion. Peptides predicted to be released following in silico 86 
gastrointestinal digestion were tested in vitro for both their DPP-IV inhibitory and antioxidant 87 
potential. 88 
 89 
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2. Materials and methods 90 
2.1. Reagents 91 
Asn-Pro, Leu-Pro, Gln-Pro, Gly-Pro, Tyr-Pro, Ile-Pro, Val-Arg, Ile-Thr-Pro, Lys-His-Pro, His-92 
Gln-Pro, Lys-Tyr-Pro, Val-Glu-Pro, Ile-Gln-Pro, Trp-Ile-Gln-Pro, Asn-Ser-Leu-Pro, Val-Leu-93 
Gly-Pro, Phe-Leu-Gln-Pro and Val-Arg-Gly-Pro were from Thermo Fisher Scientific (Ulm, 94 
Germany). Tris(hydroxymethyl)aminomethane (TRIS), 2,2-diphenyl-1-picrylhydrazyl (DPPH), 95 
6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (Trolox
TM
), Gly-Pro-pNA, diprotin A 96 
(Ile-Pro-Ile), ethanol and porcine DPP-IV (≥ 10 Units.mg-1 protein) were obtained from Sigma 97 
Aldrich (Dublin, Ireland). HPLC grade water and hydrochloric acid were from VWR (Dublin, 98 
Ireland). 99 
2.2. In silico digestion of the caseins with prolyl oligopeptidase 100 
The caseins (αs1-, αs2-, β- and κ-casein) were digested in silico with a prolyl oligopeptidase (EC 101 
3.4.21.26) activity to release peptides with a Pro residue at the C terminus. This enzyme 102 
potentially cleaves at the Pro C side of Pro-Xaa sequences, with Xaa being an amino acid 103 
different from Pro. Less effective cleavage at the Ala C-side of Ala-Xaa has also been reported 104 
(Polgar, 1992). Fifteen selected di-, tri- and tetra-peptide candidates (Tyr-Pro, Leu-Pro, Asn-Pro, 105 
Ile-Pro, Gly-Pro, Ile-Thr-Pro, His-Gln-Pro, Lys-Tyr-Pro, Lys-His-Pro, Val-Glu-Pro, Trp-Ile-Gln-106 
Pro, Val-Leu-Gly-Pro, Phe-Leu-Gln-Pro, Asn-Ser-Leu-Pro and Val-Arg-Gly-Pro) were 107 
synthesised and subsequently evaluated for their DPP-IV inhibitory and DPPH scavenging 108 
properties. 109 
 110 
Eight DPP-IV inhibitory peptides identified within the 15 peptides evaluated herein were also 111 
subjected to in silico digestion with pepsin (pH 1.3 and pH > 2), trypsin and chymotrypsin (high 112 
and low specificity) using the peptide cutter programme (ExPASy, 2011) in order to predict their 113 
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stability to gastrointestinal digestion. The peptide fragments predicted to be released on 114 
incubation with these enzymes were tested for their DPP-IV inhibitory and DPPH scavenging 115 
properties. 116 
2.3. DPP-IV inhibition assay 117 
Peptides were dispersed in HPLC grade water at concentrations ranging from 12.5 × 10
-3
 to 1.25 118 
mg.mL
-1
. The DPP-IV inhibition assay was carried out as described by Nongonierma and 119 
FitzGerald (2013a). Briefly, the test samples (25L) were pipetted onto a 96 well microplate 120 
(Sarstedt, Dublin, Ireland) containing Gly-Pro-pNA, the reaction substrate (50 L, final 121 
concentration 0.2 mM). The negative control contained 100 mM Tris-HCl buffer pH 8.0 (25L) 122 
and the reaction substrate Gly-Pro-pNA. The reaction was initiated by the addition of DPP-IV 123 
(L, final concentration 0.0025 Units.mL-1). All the reagents and samples were diluted in 100 124 
mM Tris-HCl buffer pH 8.0. Diprotin A was used as a positive control. Each sample was 125 
analysed in triplicate. The microplate was incubated at 37C for 60 min in a microplate reader 126 
(Biotek Synergy HT, Winoosky, VT, USA), absorbance of the released pNA was monitored at 127 
405 nm. DPP-IV IC50 values were determined by plotting the percentage of inhibition as a 128 
function of the concentration of test compound. 129 
Lineweaver-Burk analysis was used to study the mode of inhibition as previously described 130 
(Nongonierma & FitzGerald, 2013a). The initial rate of the reaction (pNA released from Gly-Pro-131 
pNA) was measured at different Gly-Pro-pNA concentrations ranging between 0.2 and 0.6 mM in 132 
the presence and absence of the DPP-IV peptide inhibitors at their IC50 concentration. The 133 
affinity constant (Km, without inhibitor), the apparent affinity constant (Kapp, with inhibitor) and 134 
the maximum rate of the reaction (Vmax) were determined from the double reciprocal plots. 135 
2.4. DPPH radical scavenging assay 136 
The DPPH assay was used to determine the radical scavenging properties of the peptides which 137 
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were dispersed in HPLC grade water at concentrations ranging from 1.25 × 10
-2
 to 1.25 mg.mL
-1
. 138 
The DPPH scavenging assay was carried out essentially according to Nongonierma and 139 
FitzGerald (2013a). Briefly, the test samples (50L) were pipetted onto a 96 well microplate 140 
containing a DPPH (150L, final concentration 0.088 mM) solution in 50 % (v/v) ethanol. The 141 
microplate was incubated at 37C for 60 min in a microplate reader, absorbance of the DPPH 142 
radical was monitored at 517 nm. Each sample was analysed in triplicate. Trolox was used as a 143 
positive control. Scavenging of the DPPH radical was determined with respect to a control 144 
without scavenger (DPPH solution with 50 L water) as described by Liu et al. (2005). The 145 
DPPH scavenging EC50 values (concentration of active compound required to observe 50 % 146 
DPPH scavenging) were determined by plotting the percentage of DPPH scavenged as a function 147 
of the concentration of test compound. 148 
2.5. Statistical analysis 149 
Means comparison was carried out with a one way ANOVA followed by a Student Newman-150 
Keuls test using SPSS (version 9, SPSS Inc., Chicago, IL, USA) at a significance level of P < 151 
0.05. 152 
3. Results 153 
3.1. In silico digestion of caseins and casein-derived peptides 154 
Peptides containing Pro residues have been of much interest in the area of bioactive peptides 155 
research (Hatanaka et al., 2012; Norris & FitzGerald, 2013). Peptides with a Pro residue at the C 156 
terminus may be released by the hydrolytic action of prolyl oligopeptidase (Polgar, 1992). 157 
Therefore, in silico digestion of the caseins (αs1-, αs2-, β- and κ-casein) was conducted with this 158 
enzyme activity. To date, most food protein-derived peptides with DPP-IV inhibitory properties 159 
have been shown to be short sequences between 2 and 8 amino acid residues in length (Hatanaka 160 
et al., 2012; Lacroix & Li-Chan, 2012b; Nongonierma & FitzGerald, 2013a; Tulipano et al., 161 
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2011). In addition, some short milk-derived peptides have been shown to survive gastro-intestinal 162 
digestion in vitro and in vivo (Foltz et al., 2007; Foltz, van Buren, Klaffke, & Duchateau, 2009). 163 
For this reason, selected short peptides (≤ 4 amino acid residues) with a Pro residue at the C 164 
terminus predicted to be released on incubation of the caseins with prolyl oligopeptidase were 165 
considered herein. Fig. 1 depicts the locations in the primary sequence of the individual caseins 166 
of these short peptides (underlined and boxed sequences). Of the 20 short peptides predicted to be 167 
released, fifteen (Tyr-Pro, Leu-Pro, Asn-Pro, Ile-Pro, Gly-Pro, Ile-Thr-Pro, His-Gln-Pro, Lys-168 
Tyr-Pro, Lys-His-Pro, Val-Glu-Pro, Trp-Ile-Gln-Pro, Val-Leu-Gly-Pro, Phe-Leu-Gln-Pro, Asn-169 
Ser-Leu-Pro and Val-Arg-Gly-Pro) were selected for the study herein. The location of these 170 
peptides on αs1-, αs2-, β- and κ-casein is illustrated in Fig. 1 (boxed sequences). β-Casein 171 
contained the highest number (16) of short peptides with a Pro residue at the C terminus which 172 
were predicted to be released on incubation with prolyl oligopeptidase. αs2-Casein contained the 173 
lowest number (2) of short peptides with a Pro residue at the C terminus predicted to be released 174 
on incubation with prolyl oligopeptidase. Larger peptides (between 5 and 8 amino acid length), 175 
may also be released on incubation of the caseins with prolyl oligopeptidase. For example, three 176 
peptides containing 6-7 amino acids (Ile-Lys-His-Gln-Gly-Leu-Pro, Gln-Leu-Glu-Ile-Val-Pro and 177 
Ser-Phe-Ser-Asp-Ile-Pro) were predicted to be released on incubation of αs1-casein with prolyl 178 
oligopeptidase. However, these peptides were not evaluated herein because the focus of this study 179 
was on short peptides. 180 
3.2. DPP-IV inhibition of casein-derived peptides 181 
Of the 15 peptides with a Pro residue at the C terminus studied herein, 8 (Phe-Leu-Gln-Pro, Ile-182 
Pro, Trp-Ile-Gln-Pro, Val-Leu-Gly-Pro, Tyr-Pro, Leu-Pro, Val-Arg-Gly-Pro and Asn-Pro) were 183 
DPP-IV inhibitors and 7 (Gly-Pro, His-Gln-Pro, Ile-Thr-Pro, Lys-His-Pro, Lys-Tyr-Pro, Asn-Ser-184 
Leu-Pro and Val-Glu-Pro) were inactive. The IC50 values of the different DPP-IV inhibitory 185 
peptides was determined. The most potent compound tested was Phe-Leu-Gln-Pro with an IC50 186 
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value of 65.3 ± 3.5 µM and the least potent was Asn-Pro with an IC50 value > 20,000 µM (Table 187 
1).  188 
3.3. In silico gastrointestinal digestion of DPP-IV inhibitory peptides 189 
In silico digestion with gastrointestinal enzyme activities was subsequently carried out on the 190 
eight casein-derived peptides which inhibited DPP-IV (Table 1). Of the eight DPP-IV inhibitory 191 
peptides studied herein, two (Asn-Pro and Ile-Pro) could not theoretically be further cleaved by 192 
pepsin, trypsin and chymotrypsin and six (Tyr-Pro, Leu-Pro, Trp-Ile-Gln-Pro, Val-Leu-Gly-Pro, 193 
Phe-Leu-Gln-Pro and Val-Arg-Gly-Pro) were theoretically cleaved. The different cleavage sites 194 
on these six peptides for pepsin, trypsin and chymotrypsin are illustrated in Fig. 2. In silico 195 
gastrointestinal digestion of Tyr-Pro yields Tyr and Pro, while Leu-Pro yields Leu and Pro; Trp-196 
Ile-Gln-Pro yields Trp and Ile-Gln-Pro; Val-Leu-Gly-Pro yields Val, Leu and Gly-Pro; Phe-Leu-197 
Gln-Pro yields Phe, Leu and Gln-Pro; and Val-Arg-Gly-Pro yields Val-Arg and Gly-Pro. The 198 
predicted breakdown products were subsequently evaluated experimentally for their DPP-IV 199 
inhibitory and DPPH scavenging activity. 200 
 201 
The predicted breakdown peptides (Val-Arg, Gln-Pro, Ile-Gln-Pro and Gly-Pro), of the 6 peptides 202 
(Tyr-Pro, Leu-Pro, Trp-Ile-Gln-Pro, Val-Leu-Gly-Pro, Phe-Leu-Gln-Pro and Val-Arg-Gly-Pro) 203 
predicted to be susceptible to gastrointestinal enzyme digestion, were tested for their DPP-IV 204 
inhibitory potential. Apart from Gly-Pro, which was predicted to be released by chymotryptic 205 
action on Val-Leu-Gly-Pro and the tryptic action of Val-Arg-Gly-Pro, all the other breakdown 206 
peptides (Val-Arg, Ile-Gln-Pro and Gln-Pro) were DPP-IV inhibitors. However, these were not 207 
potent DPP-IV inhibitors as their IC50 values ranged from 826.1 ± 30.1 to > 4,000 µM (Table 1). 208 
Trp and Leu, which were predicted to be released from four peptides (Leu-Pro, Trp-Ile-Gln-Pro, 209 
Val-Leu-Gly-Pro and Phe-Leu-Gln-Pro), have previously been identified as weak DPP-IV 210 
inhibitors with IC50 values of 4280 ± 48 and 3419 ± 56 µM, respectively (Nongonierma, Mooney, 211 
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Shields, & FitzGerald, 2013). 212 
The milk protein origin of the peptides studied herein is indicated in Table 1. These peptides were 213 
found within different caseins (αs1-, αs2-, β- and κ-casein). Interestingly, six (Ile-Pro, Tyr-Pro, 214 
Leu-Pro, Val-Arg, Gln-Pro and Asn-Pro) of the casein-derived DPP-IV inhibitory peptides 215 
studied herein can also be found in the whey proteins (Table 1). This has potential implications 216 
for the DPP-IV inhibitory properties of whole milk protein and for whey protein hydrolysates as 217 
these peptides may be released by enzymatic fragmentation. 218 
3.4. Mode of DPP-IV inhibition of casein-derived peptides 219 
The type of DPP-IV inhibition with the positive control (Ile-Pro-Ile) and the 7 most potent 220 
peptides (Phe-Leu-Gln-Pro, Ile-Pro, Trp-Ile-Gln-Pro, Val-Leu-Gly-Pro, Tyr-Pro, Leu-Pro and 221 
Val-Arg) studied herein was determined using the Lineweaver-Burk reciprocal representation. 222 
The Lineweaver-Burk double reciprocal plots for the positive control (Ile-Pro-Ile), Phe-Leu-Gln-223 
Pro, Ile-Pro, Trp-Ile-Gln-Pro, Val-Leu-Gly-Pro and Val-Arg are illustrated in Fig. 3. A 224 
significant difference in Vmax (P < 0.05) in the presence and absence of DPP-IV inhibitor was 225 
observed for Trp-Ile-Gln-Pro and Val-Arg. In contrast, the Kapp (in the presence of inhibitor) 226 
values were not significantly different (P ≥ 0.05) from the Km (without inhibitor) value (Fig. 3D 227 
and 3F). These results showed that Trp-Ile-Gln-Pro and Val-Arg behaved as non-competitive 228 
inhibitors of DPP-IV. There was no significant difference in Vmax (P ≥ 0.05) in the presence and 229 
absence of DPP-IV inhibitor, for the other peptides studied (Ile-Pro-Ile, Phe-Leu-Gln-Pro, Ile-230 
Pro, Val-Leu-Gly-Pro, Tyr-Pro and Leu-Pro). In contrast, the Kapp values for these peptides were 231 
significantly different (P < 0.05) from the Km value (Fig. 3A, 3B, 3C and 3E). These results 232 
indicate that these peptides behaved as competitive inhibitors of DPP-IV. 233 
 234 
3.5. Antioxidant activity of the casein-derived peptides 235 
The antioxidant behaviour of the peptides was studied by determination of their ability to 236 
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scavenge the DPPH radical. Of the 18 different peptides studied herein, only 6 (Trp-Ile-Gln-Pro, 237 
Asn-Pro, His-Gln-Pro, Lys-Tyr-Pro, Tyr-Pro and Gly-Pro) were DPPH scavengers. Twelve 238 
peptides (Leu-Pro, Gln-Pro, Ile-Pro, Val-Arg, Ile-Thr-Pro, Lys-His-Pro, Val-Glu-Pro, Ile-Gln-239 
Pro, Asn-Ser-Leu-Pro, Val-Leu-Gly-Pro, Phe-Leu-Gln-Pro and Val-Arg-Gly-Pro) did not possess 240 
DPPH scavenging activity. The antioxidant potency was evaluated by determining the EC50 241 
value. The EC50 value ranged from 2.1 ± 0.1 to > 15 mM for Trp-Ile-Gln-Pro and Gly-Pro, 242 
respectively (Table 2). Three of the antioxidant peptides described in Table 2 (Trp-Ile-Gln-Pro, 243 
Tyr-Pro and Asn-Pro), were also DPP-IV inhibitors. The 3 other antioxidative peptides (His-Gln-244 
Pro, Lys-Tyr-Pro and Gly-Pro) did not inhibit DPP-IV. 245 
4. Discussion 246 
Several studies have suggested that the presence of a Pro residue within a given peptide may be a 247 
good indicator for its DPP-IV inhibitory potential (Hatanaka et al., 2012; Uenishi et al., 2012). It 248 
has also been shown that various dipeptides with a Pro residue at the C terminus behave as DPP-249 
IV inhibitors (Hatanaka et al., 2012). Hatanaka et al. (2012) studied 16 different Pro containing 250 
dipeptides, 14 of which were DPP-IV inhibitors. Similarly, we also found herein that Ile-Pro, 251 
Tyr-Pro and Leu-Pro were DPP-IV inhibitors. In agreement with the study of Hatanaka et al. 252 
(2012), we found that Gly-Pro had no DPP-IV inhibitory activity. The DPP-IV inhibitory activity 253 
of two other dipeptides with a Pro at the C terminus (Gln-Pro and Asn-Pro), which to our 254 
knowledge have not previously been mentioned in the literature, was reported herein. However, 255 
their DPP-IV IC50 values were high (> 4000 µM, Table 1). Larger peptides (with 3-4 amino acid 256 
residues) having a Pro residue at the C terminus including Phe-Leu-Gln-Pro, Trp-Ile-Gln-Pro, 257 
Val-Leu-Gly-Pro and Val-Arg-Gly-Pro were also DPP-IV inhibitors (Table 1). In contrast, His-258 
Gln-Pro, Ile-Thr-Pro, Lys-His-Pro, Lys-Tyr-Pro, Val-Glu-Pro and Asn-Ser-Leu-Pro were not able 259 
to inhibit DPP-IV even though they had a Pro residue at the C terminus. Phe-Leu-Gln-Pro was 260 
found to be the most potent peptide studied herein, which was predicted in silico to be released by 261 
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prolyl oligopeptidase digestion of β-casein, having an IC50 of 65.3 ± 3.5 µM (Table 1). This 262 
peptide was ~ 20 times less potent that the positive control Ile-Pro-Ile (diprotin A). Other milk 263 
protein-derived peptides with a potency of the same order as Phe-Leu-Gln-Pro have previously 264 
been identified as DPP-IV inhibitory peptides including Ile-Pro-Ile-Gln-Tyr, Ile-Pro-Ala-Val-265 
Phe, Leu-Pro-Gln-Asn-Ile-Pro-Pro-Leu, Ile-Pro-Ala, Trp-Val, with IC50 values of 35, 45, 46, 49 266 
and 66 µM, respectively (Nongonierma & FitzGerald, 2013a, 2014; Silveira et al., 2013; 267 
Tulipano et al., 2011; Uenishi et al., 2012). Another DPP-IV inhibitory peptide, Met-Trp-Pro, the 268 
N terminal sequence of the human immunodeficiency virus-1 (HIV-1) transactivator Trp2-Tat 269 
(f1-3), containing a Pro at the C terminus has been reported in the literature (Lorey et al., 2003). 270 
However, for most DPP-IV inhibitory peptides comprising of more than 2 amino acids including 271 
a Pro residue, the Pro residue has been found at position 2 or 3 in the peptide (Hoffmann et al., 272 
1995; Nongonierma & FitzGerald, 2014; Silveira et al., 2013; Uenishi et al., 2012). It has also 273 
been demonstrated that these specific sequences are more likely to behave as substrate-type 274 
inhibitors of DPP-IV (Nongonierma & FitzGerald, 2014; Rahfeld, Schierborn, Hartrodt, Neubert, 275 
& Heins, 1991). Substrate-type inhibition involves inhibitors which may be further cleaved by the 276 
biomarker enzyme, releasing less potent inhibitory compounds than the parent peptide (Fujita & 277 
Yoshikawa, 1999; Nongonierma & FitzGerald, 2014).  278 
Six short (≤ 4 amino acid residues) peptides (Arg-Pro, Phe-Pro, Val-Pro, His-Pro, Leu-Pro-Pro 279 
and Thr-Ser-Thr-Pro) which were predicted to be released from caseins on incubation with prolyl 280 
oligopeptidase (Fig. 1), were not evaluated herein. Arg-Pro, Phe-Pro, Val-Pro and His-Pro were 281 
previously shown to be DPP-IV inhibitors (Hatanaka et al., 2012). To our knowledge, Leu-Pro-282 
Pro and Thr-Ser-Thr-Pro have not been shown to possess DPP-IV inhibitory activity. Larger 283 
peptides (> 5 amino acid residues) may also be released from caseins by prolyl oligopeptidase 284 
(Fig. 1). However, these may be unstable to gastrointestinal enzyme digestion and therefore were 285 
not included in the study herein.  286 
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 287 
Different modes of DPP-IV inhibition were highlighted herein with the casein-derived peptides. 288 
In agreement with previous results, we also found that the Ile-Pro-Ile and Ile-Pro were 289 
competitive inhibitors of DPP-IV (Hatanaka et al., 2012; Rahfeld et al., 1991). Most food-derived 290 
DPP-IV inhibitory peptides identified to date have been described as competitive inhibitors 291 
(Hatanaka et al., 2012; Nongonierma & FitzGerald, 2013a; Tulipano et al., 2011). Similarly, 292 
most peptides studied herein were competitive inhibitors, which indicates their direct binding to 293 
the active site of DPP-IV. However, two peptides (Trp-Ile-Gln-Pro and Val-Arg) were found to 294 
be non-competitive inhibitors of DPP-IV. It has been shown that peptides derived from the N 295 
terminus of the HIV-1 transactivator Tat could bind to a secondary site in DPP-IV, giving a linear 296 
mixed- or parabolic mixed-type inhibition (Lorey et al., 2003). Recently, a milk-derived 297 
dipeptide Trp-Val (α-La (f26-27)) which behaved as a non-competitive inhibitor of DPP-IV has 298 
been identified. Using a molecular docking approach it was shown that Trp-Val was likely to 299 
bind DPP-IV at a secondary binding site located in proximity to the active site (Nongonierma et 300 
al., 2013). Another mechanism for DPP-IV inhibition has recently been described for larger 301 
peptides (> 13 amino acid residues) where the peptides hinder the formation of the active dimeric 302 
form of DPP-IV (Velarde-Salcedo et al., 2013). 303 
 304 
An increase in oxidative stress is generally found in T2D subjects due to a compromised 305 
antioxidative system associated with changes in superoxide dismutase, glutathione peroxidase 306 
and catalase activity. This increase in oxidative stress has been linked with the development of 307 
cardiovascular and renal disease (Hadi & Al Suwaidi, 2007). It has been suggested that dietary 308 
antioxidants may act through the activation of the antioxidant system of the body, involving the 309 
nuclear factor like 2 (Nrf2) pathway (Lacroix & Li-Chan, 2014). Therefore, the antioxidant 310 
properties of milk-derived peptides could be further exploited to reduce oxidative stress in T2D 311 
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subjects. The in vitro antioxidant properties of casein-derived peptides have been well 312 
documented (Pihlanto, 2006; Power et al., 2013). However, translation of in vitro antioxidant 313 
capacity of dietary components in humans and their positive role in the prevention of T2D has yet 314 
to be demonstrated (Chang & Chuang, 2010; Lacroix & Li-Chan, 2014; Power et al., 2013).  The 315 
peptides evaluated herein only had a modest DPPH scavenging activity compared to other 316 
peptides reported in the literature. EC50 values of around 10 µM have been reported for DPPH 317 
scavenging by decapeptides extracted from venison (Kim et al., 2009), while a value of 98 µM 318 
for the casein-derived peptide Tyr-Pro-Tyr-Pro-Glu-Leu and an EC50 value of 23 µM for 319 
carnosine (Ala-His) were reported (Suetsuna et al., 2000). EC50 values of 242 and 654 µM have 320 
previously been reported for Trp-Val and Val-Trp, respectively (Nongonierma & FitzGerald, 321 
2013a). Three peptides (Asn-Pro, Tyr-Pro and Trp-Ile-Gln-Pro) evaluated herein had a dual 322 
bioactivity combining antioxidant and DPP-IV inhibitory properties. Trp-Ile-Gln-Pro (IC50 237.3 323 
± 1.3 µM) was the most potent DPP-IV inhibitor which also behaved as a DPPH (EC50 2.1 ± 0.1 324 
mM) scavenger (Tables 1 and 2). 325 
 326 
Some of the fragments which were predicted to be released from the parent peptides after in silico 327 
digestion with gastrointestinal enzymes were also subsequently experimentally shown to have 328 
DPP-IV inhibitory properties (Table 1). In general, peptides or amino acids (Nongonierma et al., 329 
2013) which were predicted to be released by gastrointestinal digestion of the casein-derived 330 
peptides had a lower DPP-IV inhibitory potential compared to the parent peptide. The exception 331 
was Val-Arg which was > 3 times more potent than the parent peptide (Val-Arg-Gly-Pro). In the 332 
case of Phe-Leu-Gln-Pro and Trp-Ile-Gln-Pro, in silico digestion with gastrointestinal enzymes 333 
resulted in peptides with > 10 fold decrease in the DPP-IV inhibitory potency. While some of the 334 
peptides were predicted to be unstable to gastrointestinal enzymes, the second most potent C 335 
terminal Pro DPP-IV inhibitor evaluated herein, Ile-Pro (DPP-IV IC50 149.6 ± 6.1 µM), was 336 
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predicted to be stable to gastrointestinal digestion. It has been demonstrated elsewhere that Ile-337 
Pro was stable to intestinal in vitro digestion, with > 75% intact dipeptide remaining after 60 min 338 
of simulated intestinal digestion (Foltz et al., 2009). These results would indicate that Ile-Pro 339 
would be bioavailable. However, the bioavailability and efficacy of Ile-Pro needs to be evaluated 340 
in vivo in order to validate the results described herein. It is interesting to note that Ile-Pro is 341 
present in the primary sequence of several milk proteins (Table 1). 342 
 343 
The results described herein using a combined in silico and experimental strategy further 344 
demonstrate that peptides with a Pro residue at the C terminus were not always associated with 345 
DPP-IV inhibitory activity. In addition, some of the C-terminal Pro peptides had a relatively low 346 
DPP-IV inhibitory potency. There appear to be other physicochemical characteristics which may 347 
play a role in the binding of peptides to the active site of DPP-IV, affecting their inhibitory 348 
properties. Studies involving reverse peptides (Hatanaka et al., 2012; Nongonierma & FitzGerald, 349 
2013a) have demonstrated that peptide sequence appears to be a primary determinant for its DPP-350 
IV inhibitory potential. However, more research is required to fully establish which 351 
physicochemical characteristics of peptides are linked with their DPP-IV inhibitory potential. The 352 
results described herein are solely based on in silico prediction of peptide release with different 353 
enzymatic activities including prolyl oligopeptidase, pepsin, chymotrypsin and trypsin. 354 
Validation of the in silico prediction with in vitro digestion of caseins with the relevant enzymes 355 
would help to confirm the results described herein. Ultimately, in vivo testing of the hydrolysates 356 
generated should be conducted to study the stability and biological activity of these peptides in 357 
humans. 358 
Conclusion 359 
The work flow described herein allowed use of in silico analysis to predict peptide sequences 360 
with DPP-IV inhibitory properties and to predict their stability to gastrointestinal digestion. This 361 
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has allowed determination of potent casein-derived DPP-IV inhibitory peptides some of which 362 
were predicted to be stable to gastrointestinal enzyme digestion. The application of relevant 363 
enzyme activities during hydrolysis may help to specifically release these fragments with the 364 
view to developing more potent DPP-IV inhibitory milk protein-derived hydrolysates. The 365 
findings described herein are relevant to the development of milk protein hydrolysates for 366 
application as functional food ingredients with serum glucose lowering and antioxidative 367 
properties in the management of T2D. 368 
369 
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Table captions 
 
Table 1 Inhibitory concentration inducing 50 % inhibition (IC50) of dipeptidyl peptidase IV 
(DPP-IV) in the presence of short (≤ 4 amino acid residues) casein-derived C terminal proline 
containing peptides, type of inhibition and milk protein source of DPP-IV inhibitory peptides. 
The 15 selected C terminal proline containing peptides predicted to be released from casein 
following enzymatic digestion with prolyl oligopeptidase are indicated in bold. 
 
Table 2 Inhibitory concentration inducing 50 % scavenging (EC50) for 2,2-diphenyl-1-
picrylhydrazyl (DPPH) in the presence of short (≤ 4 amino acid residues) casein-derived C 
terminal proline containing peptides. 
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Table 1 




Milk protein source 
Ile-Pro-Ile 3.5 ± 0.2
a
 competitive positive control (diprotin A) κ-CN (f26-28) 
Phe-Leu-Gln-Pro 65.3 ± 3.5
b
 competitive β-CN (f87-90) 
Ile-Pro 149.6 ± 6.1
c
 competitive β-CN (f66-67), β-CN (f74-75), αs1-CN (f 182-183), αs2-CN (f201-202), κ-CN 
(f26-27), κ-CN (f108-109), κ-CN (f119-120), β-Lg (f78-79), BSA (f297-298), 
LF (f127-128), LF (f310-311), LF (f469-470) 
Trp-Ile-Gln-Pro 237.3 ± 1.3
d
 non-competitive αs2-CN (f193-196) 
Val-Leu-Gly-Pro 580.4 ± 11.3
e
 competitive β-CN (f197-200) 
Tyr-Pro 658.1 ± 8.0
e
 competitive β-CN (f60-61), β-CN (f114-115), β-CN (f180-181), αs1-CN (f146-147), αs1-
CN (f159-160), κ-CN (f35-36), κ-CN (f68-69), LF (f166-167) 
Leu-Pro 712.5 ± 11.0
e
 competitive β-CN (f135-136), β-CN (f137-138), β-CN (f151-152), β-CN (f171-172), αs1-
CN (f11-12), αs2-CN (f176-177), κ-CN (f56-57), β-Lg (f143-144), α-La (f23-
24), BSA (f112-113), BSA (f179-179), BSA (f301-302), BSA (f515-516), LF 
(f218-219) 
  27 
Val-Arg 826.1 ± 30.1
f
 non-competitive β-CN (f201-202), κ-CN (f67-68), β-Lg (f123-124), BSA (f398-399), LF (f6-
7), LF (f37-38) 
Val-Arg-Gly-Pro > 3,000 nd β-CN (f201-204) 
Gln-Pro > 4,000 nd β-CN (f89-90), β-CN (f146-147), β-CN (f149-150), αs2-CN (f195-196), κ-CN 
(f7-8), LF (f13-14) 
Ile-Gln-Pro > 4,000 nd αs2-CN (f194-196) 
Asn-Pro > 20,000 nd αs1-CN (f184-185), αs2-CN (f29-30), αs2-CN (f107-108), β-Lg (f152-153), α-
La (f66-67) 
Gly-Pro - na β-CN (f64-65), β-CN (f199-200), β-CN (f203-204), αs2-CN (f102-103), BSA 
(f571-572) 
His-Gln-Pro - na β-CN (f145-147), β-CN (f148-150) 
Ile-Thr-Pro - na αs2-CN (f119-121) 
Lys-His-Pro - na αs1-CN (f3-5) 
Lys-Tyr-Pro - na β-CN (f113-115) 
Asn-Ser-Leu-Pro - na β-CN (f68-71) 
  28 
Val-Glu-Pro - na β-CN (f116-118) 
Values represent mean IC50 values ± confidence interval (P = 0.05) n=3 and triplicate determination. Values with different superscript 
letter are significantly different (P < 0.05)  
The selected C terminal proline containing peptides predicted to be released from casein following enzymatic digestion with prolyl 
oligopeptidase are indicated in bold 
IC50 values and type of inhibition for Ile-Pro, Tyr-Pro and Leu-Pro were taken from Nongonierma and FitzGerald (2014) 
Type of inhibition determined using Lineweaver-Burk plots as described in Nongonierma & FitzGerald (2012); nd: not determined, na: 
not applicable; -: no DPP-IV inhibition 
α-La: α-lactalbumin; β-Lg : β-lactoglobulin; BSA: bovine serum albumin; CN: casein; LF: lactoferrin. 





Compound DPPH EC50 (mM) 














Values represent mean EC50 values ± confidence interval (P = 0.05) n=3 
and triplicate determination. Values with different superscript letter are 
significantly different (P < 0.05) 
Values for
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Figure captions 
 
Fig 1. Peptide mapping of the short peptides (≤ 4 amino acid residues)  with a proline 
residue at the C terminus, which can theoretically be released by in silico digestion with 
a prolyl oligopeptidase activity (using one letter amino acid code). The fifteen casein-
derived peptides studied herein are boxed and the other sequences are underlined, the 
proline residues are indicated in bold. 
 
Fig 2. In silico digestion of casein-derived C-terminal proline containing dipeptidyl 
peptidase IV (DPP-IV) inhibitory peptides with gastrointestinal enzymes. Possible 
cleavage sites on various peptides by pepsin (P), trypsin (T) and chymotrypsin (C) are 
indicated by an arrow. 
 
Fig 3. Lineweaver-Burk double reciprocal plots for dipeptidyl peptidase IV (DPP-IV) 
inhibition with casein-derived peptides at their half maximum inhibitory concentration 
(IC50). (A) Ile-Pro-Ile (B) Phe-Leu-Gln-Pro, (C) Ile-Pro, (D) Trp-Ile-Gln-Pro, (E) Val-
Leu-Gly-Pro and (F) Val-Arg. Values are the mean of three determinations (n=3)  SD. 
Vi: initial velocity. 
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αs1-casein, variant B 
RP KHP IKHQGLPQEVLNENLLRFFVAP FP EVFGKEKVNELSKDIGSESTEDQAMED 
IKQMEAESISSSEEIVPNSVEQKHIQKEDVPSERYLGYLEQLLRLKKYKVPQLEIVPNS
AEERLHSMKEGIHAQQKEPMIGVNQELAYFYPELFRQFYQLDAYPSGAWYYVPLGT
QYTDAPSFSDIP NP IGSENSEKTTMPLW 
 
αs2-casein, variant A 
KNTMEHVSSSEESIISQETYKQEKNMAINPSKENLCSTFCKEVVRNANEEEYSIGSSSE
ESAEVATEEVKITVDDKHYQKALNEINQFYQKFPQYLQYLYQGPIVLNPWDQVKRN
AVP ITP TLNREQLSTSEENSKKTVDMESTEVFTKKTKLTEEEKNRLNFLKKISQRYQ 
KFALPQYLKTVYQHQKAMKP WIQP KTKVIPYVRYL 
 
β-casein, variant A2 
RELEELNVPGEIVESLSSSEESITRINKKIEKFQSEEQQQTEDELQDKIHPFAQTQSLVY
P FP GP IP NSLP QNIPPLTQTPVVVPP FLQP EVMGVSKVKEAMAPKHKEMP FP 
KYP VEP FTESQSLTLTDVENLHLP LP LLQSWMHQP HQP LPP TVMFPPQSVLSLS 
QSKVLP VP QKAVP YP QRDMPIQAFLLYQEP VLGP VRGP FP IIV 
 
κ-casein, variant A 
QEQNQEQPIRCEKDERFFSDKIAKYIPIQYVLSRYPSYGLNYYQQKPVALINNQFLP 
YP YYAKPAAVRSPAQILQWQVLSNTVPAKSCQAQPTTMARHP HP HLSFMAIPPK 
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Fig 3. 
